Does neuroendocrine like tumor pathology impact neoadjuvant chemotherapy response precystectomy

Affiliations

¹ Department of Oncology, Mount Vernon Cancer Centre, London, UK.
² Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK; School of Medicine and Life Sciences, University of Hertfordshire, UK. Electronic address: nikhil.vasdev@nhs.net.

Comment

Anand Sharma et al. Urol Oncol. 2020 May.

. 2020 May;38(5):555.

doi: 10.1016/j.urolonc.2019.12.001. Epub 2019 Dec 18.

¹ Department of Oncology, Mount Vernon Cancer Centre, London, UK.
² Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK; School of Medicine and Life Sciences, University of Hertfordshire, UK. Electronic address: nikhil.vasdev@nhs.net.

No abstract available

Comment on

Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.
Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y. Grivas P, et al. Urol Oncol. 2020 Apr;38(4):262-268. doi: 10.1016/j.urolonc.2019.11.004. Epub 2019 Dec 4. Urol Oncol. 2020. PMID: 31812633